感染

订阅

MedSci主页 / 所有栏目 / 感染

Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册

2019-12-30 Allan MedSci原创

Sulopenem尿道感染Iterumtherapeutics
关注

Iterum Therapeutics是一家临床阶段的制药公司，致力于开发新型抗生素，以治疗社区和医院环境中由多重耐药性病原体引起的感染，Iterum Therapeutics近日宣布口服Sulopenem治疗尿道感染的III期临床试验已完成患者入组。

Iterum Therapeutics是一家临床阶段的制药公司，致力于开发新型抗生素，以治疗社区和医院环境中由多重耐药性病原体引起的感染，Iterum Therapeutics近日宣布口服Sulopenem治疗尿道感染的III期临床试验已完成患者入组。

Iterum Therapeutics首席执行官Corey Fishman说：“我们很高兴地宣布完成了针对尿路感染（uUTI）的III期临床试验的入组。该试验的主要结果预计将在2020年第一季度公布。如果获得批准，口服Sulopenem将为那些治疗失败风险较高的患者提供治疗手段，目前治疗失败的患者尚无其他选择”。


原始出处：

https://www.firstwordpharma.com/node/1690166?tsid=4

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1694757, encodeId=a14b1694e575f, content=<a href='/topic/show?id=6e4f4e537c1' target=_blank style='color:#2F92EE;'>#尿道感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47537, encryptionId=6e4f4e537c1, topicName=尿道感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c1129737488, createdName=mfx809, createdTime=Sat Jun 27 11:02:00 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088775, encodeId=8af32088e7552, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Mar 21 06:02:00 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931489, encodeId=d9e719314894f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Mar 12 09:02:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769157, encodeId=fbde1e69157d3, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Sun May 17 14:02:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652971, encodeId=f59d16529e1a4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Feb 13 09:02:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974383, encodeId=77af19e43838a, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Mar 28 07:02:00 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738992, encodeId=82911e3899292, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Apr 09 08:02:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728247, encodeId=98681e2824767, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 05 17:02:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916213, encodeId=6c39191621336, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Aug 29 07:02:00 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350833, encodeId=04a41350833b7, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jan 01 08:02:00 CST 2020, time=2020-01-01, status=1, ipAttribution=)]
    2020-06-27 mfx809

    #尿道感染#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1694757, encodeId=a14b1694e575f, content=<a href='/topic/show?id=6e4f4e537c1' target=_blank style='color:#2F92EE;'>#尿道感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47537, encryptionId=6e4f4e537c1, topicName=尿道感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c1129737488, createdName=mfx809, createdTime=Sat Jun 27 11:02:00 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088775, encodeId=8af32088e7552, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Mar 21 06:02:00 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931489, encodeId=d9e719314894f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Mar 12 09:02:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769157, encodeId=fbde1e69157d3, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Sun May 17 14:02:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652971, encodeId=f59d16529e1a4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Feb 13 09:02:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974383, encodeId=77af19e43838a, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Mar 28 07:02:00 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738992, encodeId=82911e3899292, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Apr 09 08:02:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728247, encodeId=98681e2824767, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 05 17:02:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916213, encodeId=6c39191621336, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Aug 29 07:02:00 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350833, encodeId=04a41350833b7, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jan 01 08:02:00 CST 2020, time=2020-01-01, status=1, ipAttribution=)]
    2020-03-21 839640778

    #I期临床试验#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1694757, encodeId=a14b1694e575f, content=<a href='/topic/show?id=6e4f4e537c1' target=_blank style='color:#2F92EE;'>#尿道感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47537, encryptionId=6e4f4e537c1, topicName=尿道感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c1129737488, createdName=mfx809, createdTime=Sat Jun 27 11:02:00 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088775, encodeId=8af32088e7552, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Mar 21 06:02:00 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931489, encodeId=d9e719314894f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Mar 12 09:02:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769157, encodeId=fbde1e69157d3, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Sun May 17 14:02:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652971, encodeId=f59d16529e1a4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Feb 13 09:02:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974383, encodeId=77af19e43838a, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Mar 28 07:02:00 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738992, encodeId=82911e3899292, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Apr 09 08:02:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728247, encodeId=98681e2824767, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 05 17:02:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916213, encodeId=6c39191621336, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Aug 29 07:02:00 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350833, encodeId=04a41350833b7, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jan 01 08:02:00 CST 2020, time=2020-01-01, status=1, ipAttribution=)]
    2020-03-12 kksonne

    #II期临床试验#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1694757, encodeId=a14b1694e575f, content=<a href='/topic/show?id=6e4f4e537c1' target=_blank style='color:#2F92EE;'>#尿道感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47537, encryptionId=6e4f4e537c1, topicName=尿道感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c1129737488, createdName=mfx809, createdTime=Sat Jun 27 11:02:00 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088775, encodeId=8af32088e7552, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Mar 21 06:02:00 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931489, encodeId=d9e719314894f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Mar 12 09:02:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769157, encodeId=fbde1e69157d3, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Sun May 17 14:02:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652971, encodeId=f59d16529e1a4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Feb 13 09:02:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974383, encodeId=77af19e43838a, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Mar 28 07:02:00 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738992, encodeId=82911e3899292, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Apr 09 08:02:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728247, encodeId=98681e2824767, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 05 17:02:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916213, encodeId=6c39191621336, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Aug 29 07:02:00 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350833, encodeId=04a41350833b7, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jan 01 08:02:00 CST 2020, time=2020-01-01, status=1, ipAttribution=)]
    2020-05-17 lifestar

    #尿道#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1694757, encodeId=a14b1694e575f, content=<a href='/topic/show?id=6e4f4e537c1' target=_blank style='color:#2F92EE;'>#尿道感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47537, encryptionId=6e4f4e537c1, topicName=尿道感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c1129737488, createdName=mfx809, createdTime=Sat Jun 27 11:02:00 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088775, encodeId=8af32088e7552, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Mar 21 06:02:00 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931489, encodeId=d9e719314894f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Mar 12 09:02:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769157, encodeId=fbde1e69157d3, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Sun May 17 14:02:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652971, encodeId=f59d16529e1a4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Feb 13 09:02:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974383, encodeId=77af19e43838a, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Mar 28 07:02:00 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738992, encodeId=82911e3899292, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Apr 09 08:02:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728247, encodeId=98681e2824767, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 05 17:02:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916213, encodeId=6c39191621336, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Aug 29 07:02:00 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350833, encodeId=04a41350833b7, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jan 01 08:02:00 CST 2020, time=2020-01-01, status=1, ipAttribution=)]
    2020-02-13 医生2402

    #I期临床#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1694757, encodeId=a14b1694e575f, content=<a href='/topic/show?id=6e4f4e537c1' target=_blank style='color:#2F92EE;'>#尿道感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47537, encryptionId=6e4f4e537c1, topicName=尿道感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c1129737488, createdName=mfx809, createdTime=Sat Jun 27 11:02:00 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088775, encodeId=8af32088e7552, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Mar 21 06:02:00 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931489, encodeId=d9e719314894f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Mar 12 09:02:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769157, encodeId=fbde1e69157d3, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Sun May 17 14:02:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652971, encodeId=f59d16529e1a4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Feb 13 09:02:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974383, encodeId=77af19e43838a, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Mar 28 07:02:00 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738992, encodeId=82911e3899292, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Apr 09 08:02:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728247, encodeId=98681e2824767, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 05 17:02:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916213, encodeId=6c39191621336, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Aug 29 07:02:00 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350833, encodeId=04a41350833b7, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jan 01 08:02:00 CST 2020, time=2020-01-01, status=1, ipAttribution=)]
    2020-03-28 ms24272190615788285182

    #Therapeutic#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1694757, encodeId=a14b1694e575f, content=<a href='/topic/show?id=6e4f4e537c1' target=_blank style='color:#2F92EE;'>#尿道感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47537, encryptionId=6e4f4e537c1, topicName=尿道感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c1129737488, createdName=mfx809, createdTime=Sat Jun 27 11:02:00 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088775, encodeId=8af32088e7552, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Mar 21 06:02:00 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931489, encodeId=d9e719314894f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Mar 12 09:02:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769157, encodeId=fbde1e69157d3, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Sun May 17 14:02:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652971, encodeId=f59d16529e1a4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Feb 13 09:02:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974383, encodeId=77af19e43838a, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Mar 28 07:02:00 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738992, encodeId=82911e3899292, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Apr 09 08:02:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728247, encodeId=98681e2824767, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 05 17:02:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916213, encodeId=6c39191621336, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Aug 29 07:02:00 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350833, encodeId=04a41350833b7, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jan 01 08:02:00 CST 2020, time=2020-01-01, status=1, ipAttribution=)]
    2020-04-09 124988c7m106暂无昵称

    #ERA#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1694757, encodeId=a14b1694e575f, content=<a href='/topic/show?id=6e4f4e537c1' target=_blank style='color:#2F92EE;'>#尿道感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47537, encryptionId=6e4f4e537c1, topicName=尿道感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c1129737488, createdName=mfx809, createdTime=Sat Jun 27 11:02:00 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088775, encodeId=8af32088e7552, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Mar 21 06:02:00 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931489, encodeId=d9e719314894f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Mar 12 09:02:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769157, encodeId=fbde1e69157d3, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Sun May 17 14:02:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652971, encodeId=f59d16529e1a4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Feb 13 09:02:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974383, encodeId=77af19e43838a, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Mar 28 07:02:00 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738992, encodeId=82911e3899292, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Apr 09 08:02:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728247, encodeId=98681e2824767, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 05 17:02:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916213, encodeId=6c39191621336, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Aug 29 07:02:00 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350833, encodeId=04a41350833b7, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jan 01 08:02:00 CST 2020, time=2020-01-01, status=1, ipAttribution=)]
    2020-02-05 feather89

    #PE#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1694757, encodeId=a14b1694e575f, content=<a href='/topic/show?id=6e4f4e537c1' target=_blank style='color:#2F92EE;'>#尿道感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47537, encryptionId=6e4f4e537c1, topicName=尿道感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c1129737488, createdName=mfx809, createdTime=Sat Jun 27 11:02:00 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088775, encodeId=8af32088e7552, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Mar 21 06:02:00 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931489, encodeId=d9e719314894f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Mar 12 09:02:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769157, encodeId=fbde1e69157d3, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Sun May 17 14:02:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652971, encodeId=f59d16529e1a4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Feb 13 09:02:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974383, encodeId=77af19e43838a, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Mar 28 07:02:00 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738992, encodeId=82911e3899292, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Apr 09 08:02:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728247, encodeId=98681e2824767, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 05 17:02:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916213, encodeId=6c39191621336, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Aug 29 07:02:00 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350833, encodeId=04a41350833b7, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jan 01 08:02:00 CST 2020, time=2020-01-01, status=1, ipAttribution=)]
    2020-08-29 juliusluan78

    #III#

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1694757, encodeId=a14b1694e575f, content=<a href='/topic/show?id=6e4f4e537c1' target=_blank style='color:#2F92EE;'>#尿道感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47537, encryptionId=6e4f4e537c1, topicName=尿道感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c1129737488, createdName=mfx809, createdTime=Sat Jun 27 11:02:00 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088775, encodeId=8af32088e7552, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Mar 21 06:02:00 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931489, encodeId=d9e719314894f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Mar 12 09:02:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769157, encodeId=fbde1e69157d3, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Sun May 17 14:02:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652971, encodeId=f59d16529e1a4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Feb 13 09:02:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974383, encodeId=77af19e43838a, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Mar 28 07:02:00 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738992, encodeId=82911e3899292, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Apr 09 08:02:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728247, encodeId=98681e2824767, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 05 17:02:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916213, encodeId=6c39191621336, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Aug 29 07:02:00 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350833, encodeId=04a41350833b7, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jan 01 08:02:00 CST 2020, time=2020-01-01, status=1, ipAttribution=)]
    2020-01-01 zhaojie88

    #therapeutics#

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

复杂腹腔内感染的治疗：口服和静脉注射Sulopenem的III期临床试验结果

Iterum Therapeutics是一家临床阶段的制药公司，致力于开发新型抗生素来治疗耐药病原体引起的感染，近日公布了Sulopenem治疗复杂腹腔内感染（cIAI）的III临床试验结果。这些结果强调了Sulopenem的潜力，有助于应对日益增长的抗生素耐药。